Atlantic Union Bankshares Corp reduced its position in shares of Eli Lilly And Co (NYSE:LLY) by 0.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,619 shares of the company’s stock after selling 124 shares during the period. Atlantic Union Bankshares Corp’s holdings in Eli Lilly And Co were worth $2,608,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Valmark Advisers Inc. grew its position in Eli Lilly And Co by 15.6% in the second quarter. Valmark Advisers Inc. now owns 2,959 shares of the company’s stock worth $486,000 after acquiring an additional 399 shares in the last quarter. Sigma Planning Corp lifted its stake in Eli Lilly And Co by 4.3% in the second quarter. Sigma Planning Corp now owns 15,339 shares of the company’s stock worth $2,518,000 after purchasing an additional 635 shares during the last quarter. Calamos Wealth Management LLC lifted its stake in Eli Lilly And Co by 117.6% in the second quarter. Calamos Wealth Management LLC now owns 3,375 shares of the company’s stock worth $554,000 after purchasing an additional 1,824 shares during the last quarter. Ellevest Inc. lifted its stake in Eli Lilly And Co by 60.8% in the second quarter. Ellevest Inc. now owns 1,105 shares of the company’s stock worth $181,000 after purchasing an additional 418 shares during the last quarter. Finally, Advisor Group Holdings Inc. bought a new stake in Eli Lilly And Co in the first quarter worth $23,711,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Several analysts have weighed in on LLY shares. ValuEngine downgraded shares of Eli Lilly And Co from a “hold” rating to a “sell” rating in a research note on Saturday. Morgan Stanley raised shares of Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $149.55 to $176.00 in a research note on Thursday, September 3rd. They noted that the move was a valuation call. Mizuho boosted their price target on shares of Eli Lilly And Co from $155.00 to $164.00 and gave the stock a “neutral” rating in a research note on Monday, June 29th. Berenberg Bank started coverage on shares of Eli Lilly And Co in a research note on Tuesday, September 29th. They issued a “hold” rating and a $144.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly And Co from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $169.62.
In related news, SVP Melissa S. Barnes sold 5,000 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $151.01, for a total transaction of $755,050.00. Following the transaction, the senior vice president now owns 23,580 shares in the company, valued at $3,560,815.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.09% of the stock is owned by corporate insiders.
Eli Lilly And Co stock traded down $0.66 during midday trading on Friday, reaching $146.12. 2,919,724 shares of the company traded hands, compared to its average volume of 3,892,467. The firm has a market capitalization of $139.76 billion, a price-to-earnings ratio of 23.72, a price-to-earnings-growth ratio of 1.35 and a beta of 0.19. The business has a 50 day moving average of $149.64 and a two-hundred day moving average of $153.41. Eli Lilly And Co has a 12 month low of $101.36 and a 12 month high of $170.75. The company has a debt-to-equity ratio of 3.53, a current ratio of 1.22 and a quick ratio of 0.94.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Thursday, July 30th. The company reported $1.89 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.58 by $0.31. The company had revenue of $5.50 billion for the quarter, compared to the consensus estimate of $5.77 billion. Eli Lilly And Co had a net margin of 24.48% and a return on equity of 183.80%. The firm’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.50 earnings per share. As a group, equities analysts forecast that Eli Lilly And Co will post 7.31 EPS for the current year.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: What is Compound Annual Growth Rate (CAGR)?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.